Anastrozole

Anastrozole (Arimidex) is a third-generation, non-steroidal, competitive reversible inhibitor of aromatase (CYP19A1). It binds the enzyme active site and prevents androgen substrate binding; inhibition reverses on drug clearance. Originally developed for adjuvant therapy in postmenopausal ER-positive breast cancer, it became the first-line AI for on-cycle E2 management in AAS protocols due to its steep dose-response curve and reversible mechanism.

Mechanism — competitive enzyme inhibition:

Anastrozole occupies the CYP19A1 active site without producing the catalytic conversion that aromatisation requires. The drug-enzyme interaction is competitive — substrate (testosterone, androstenedione) and inhibitor compete for the same binding site. Higher anastrozole concentration shifts the equilibrium toward enzyme inhibition; lower concentration releases the binding and substrate aromatisation resumes.

The reversibility distinguishes anastrozole from exemestane (suicide inhibitor producing irreversible enzyme inactivation). Practical implication: anastrozole produces a rebound estradiol elevation 2–3 days after discontinuation as the inhibition releases — a pattern users should recognise and not interpret as cycle-driven E2 spike.

Pharmacokinetics:

– Elimination half-life: ~50 hours (about 2 days)
– Steady-state achieved within 7 days of initiation
– Single-dose effect on serum estradiol: detectable within 24 hours, peak suppression at 48–72 hours
– Metabolism: primarily hepatic via CYP3A4; renal excretion of metabolites

Dosing protocol on AAS cycles:

The dose-response is steep. Mauras et al. 2003, J Clin Endocrinol Metab documented the kinetics in adolescent males — 1 mg/day suppresses serum estradiol by approximately 80%, far exceeding the suppression most AAS users need.

– Conservative start: 0.25 mg every other day (EOD) on 500 mg/week testosterone
– Standard: 0.5 mg EOD on 500 mg/week testosterone with documented elevated E2
– Aggressive: 0.5 mg daily — rarely needed; reserved for high-dose stacks with confirmed sensitive E2 above 70 pg/mL
– Oncology adjuvant dose: 1 mg/day — supratherapeutic for AAS use; produces predictable E2 crash

Dose adjustments use sensitive LC-MS/MS estradiol bloodwork as the input variable. Standard immunoassay produces 50–100% measurement error in male reference range and drives misdosed AI decisions (see Iatrogenic Hypoestrogenaemia entry).

Titration logic:

If sensitive E2 returns at 18 pg/mL, the correct response is to halve the AI dose, not to maintain. If E2 returns at 65 pg/mL with concurrent symptoms, a single 0.5 mg dose typically brings serum into the 25–40 pg/mL target range within a week. Iterative titration to measured response is the framework; preemptive dosing without bloodwork is the failure mode that produces iatrogenic hypoestrogenaemia.

Side-effect profile:

Most anastrozole side effects in AAS users are direct consequences of estradiol suppression rather than off-target effects. The clinical syndrome of crashed E2 (arthralgia, libido loss, dry eyes, mood depression, lipid degradation, accelerated bone resorption) appears reliably below 20 pg/mL serum estradiol and resolves on dose reduction.

Direct anastrozole effects independent of E2 mechanism are minimal at AAS-protocol dosing. Long-term oncology use (5+ years at 1 mg/day) produces measurable bone density loss in postmenopausal women — the AAS-protocol exposure window is shorter and the bone-resorption signal is mediated by E2 suppression rather than direct drug effect.

Anastrozole vs alternatives:

– Letrozole: more potent (5–10× anastrozole); preferred for established gynaecomastia regression rather than maintenance E2 management.
– Exemestane: irreversible suicide inhibitor; preferred for users who experience anastrozole rebound. No dose adjustment after discontinuation — recovery requires new enzyme synthesis (~5–7 days).

For routine on-cycle E2 management at testosterone doses 400–600 mg/week with documented elevation, anastrozole at 0.25–0.5 mg EOD is the standard first-line choice.